UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer

Breast cancer research and treatment, 2021, Vol.185 (1), p.135-144

2021

Volltextzugriff (PDF)

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

The lancet oncology, 2018-04, Vol.19 (4), p.497-509

2018

Volltextzugriff (PDF)

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

The lancet oncology, 2021-02, Vol.22 (2), p.212-222

2021

Volltextzugriff (PDF)

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

Cancer treatment reviews, 2013-12, Vol.39 (8), p.935-946

2013

Volltextzugriff (PDF)

Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications

Therapeutic Advances in Medical Oncology, 2016-07, Vol.8 (4), p.261-266

2016

Volltextzugriff (PDF)

Patterns of Recurrence and Outcome According to Breast Cancer Subtypes in Lymph Node–Negative Disease: Results From International Breast Cancer Study Group Trials VIII and IX

Journal of clinical oncology, 2013-09, Vol.31 (25), p.3083-3090

2013

Volltextzugriff (PDF)

Dissecting the Heterogeneity of Triple-Negative Breast Cancer

Journal of clinical oncology, 2012-05, Vol.30 (15), p.1879-1887

2012

Volltextzugriff (PDF)

Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)

Journal of clinical oncology, 2014-07, Vol.32 (20), p.2159-2165

2014

Volltextzugriff (PDF)

Pertuzumab: Optimizing HER2 Blockade

Clinical cancer research, 2013-10, Vol.19 (20), p.5552-5556

2013

Volltextzugriff (PDF)

Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab

Cancer discovery, 2021-10, Vol.11 (10), p.2474-2487

2021

Volltextzugriff (PDF)

Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade

The oncologist (Dayton, Ohio), 2019-07, Vol.24 (7), p.e441-e449

2019

Volltextzugriff (PDF)

Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial

Journal of clinical oncology, 2015-09, Vol.33 (25), p.2772-2779

2015

Volltextzugriff (PDF)

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)

The lancet oncology, 2013-03, Vol.14 (3), p.244-248

2013

Volltextzugriff (PDF)

Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)

Journal of clinical oncology, 2022-02, Vol.40 (5), p.449-458

2022

Volltextzugriff (PDF)

HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial

The Journal of clinical investigation, 2024-04, Vol.134 (7), p.1-17

2024

Volltextzugriff (PDF)

A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer

Cancer research (Chicago, Ill.), 2022-10, Vol.82 (20), p.3673-3686

2022

Volltextzugriff (PDF)

Clinical development of insulin-like growth factor receptor—1 (IGF-1R) inhibitors: At the crossroad?

Investigational new drugs, 2012-12, Vol.30 (6), p.2433-2442

2012

Volltextzugriff (PDF)

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence

Journal of Oncology, 2012-01, Vol.2012 (2012), p.251-258-029

2012

Volltextzugriff (PDF)

Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosis

Critical reviews in oncology/hematology, 2011-01, Vol.77 (1), p.20-29

2011

Volltextzugriff (PDF)

Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer with Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02)

Frontiers in oncology, 2018-01, Vol.7, p.329-329

2018

Volltextzugriff (PDF)

Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma

Dermatology Research and Practice, 2012-01, Vol.2012 (2012), p.70-78

2012

Volltextzugriff (PDF)

Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial

Journal of clinical oncology, 2013-06, Vol.31 (16), p.1954-1960

2013

Volltextzugriff (PDF)

1 – 25 von 89

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(73)

Publikationsform

Artikel
(88)
Tagungsberichte
(1)

Sprache

Englisch
(87)
Portugiesisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(57)
Life Sciences & Biomedicine
(55)
Humans
(47)
Oncology
(47)
Female
(42)
Breast Neoplasms - Drug Therapy
(31)
Breast Cancer
(28)
Breast Neoplasms - Pathology
(22)
Middle Aged
(18)
Adult
(17)
Trastuzumab
(16)
Breast Neoplasms - Genetics
(15)
Tumors
(15)
Chemotherapy
(14)
Aged
(13)
Antineoplastic Agents - Therapeutic Use
(11)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(11)
Chemotherapy, Adjuvant
(11)
Clinical Trials
(11)
Biological And Medical Sciences
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications

Patterns of Recurrence and Outcome According to Breast Cancer Subtypes in Lymph Node–Negative Disease: Results From International Breast Cancer Study Group Trials VIII and IX

Dissecting the Heterogeneity of Triple-Negative Breast Cancer

Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)

Pertuzumab: Optimizing HER2 Blockade

Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab

Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade

Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)

Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)

HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial

A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer

Clinical development of insulin-like growth factor receptor—1 (IGF-1R) inhibitors: At the crossroad?

CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence

Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial

Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosis

Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer with Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02)

Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma

Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial

Suchergebnisse filtern